Chinese Virus

Chinese Virus www.infralive.com 45 Infra LIVE April 15, 2020 of clustering onset, is more likely t o a f f e c t o l de r ma l e s wi t h comorbidities, and can result in severe and even fatal respiratory diseases such as acute respiratory distress syndrome. In general, characteristics of patients who d i ed we r e i n l i ne wi th the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia. Further investi- gation is needed to explore the applicability of the MuLBSTA score in predicting the risk of mortality in 2019-nCoV infection. Funding National Key R&D Program of China. Introduction Since Dec 8, 2019, several cases o f pneumon i a o f unknown aetiology have been reported in Wuhan, Hubei province, China. Most patients worked at or lived around the local Huanan seafood wholesale market, where live animals were also on sale. In the early stages of this pneumonia, severe acute respiratory infection symptoms occurred, with some patients rapidly developing acute respiratory distress syndrome (ARDS), acute respiratory failure, and other serious complications. On Jan 7, a novel coronavirus was identified by the Chinese Center for Disease Control and Preven- tion (CDC) from the throat swab sample of a patient, and was subsequently named 2019-nCoV byWHO. Coronav i ruses can cause multiple system infections in various animals and mainly respiratory tract infections in humans, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syn- drome (MERS). Mos t pa t i ent s have mi l d symptoms and good prognosis. So far, a few patients with 2019- nCoV have developed severe pneumonia, pulmonary oedema, ARDS, or multiple organ failure and have died. All costs of 2019- nCoV treatment are covered by Chronic medical illness 50 (51 pc) Cardiovascular & cerebrovascular diseases 40 (40 pc) Digestive system disease 11 (11 pc) Endocrine system disease (12 were diabetic) 13 (13 pc) Malignant tumour 1 (1 pc) Nervous system disease 1 (1 pc) Respiratory system disease 1 (1 pc) Admission to intensive care unit 23 (23 pc) Clinical outcome Remained in hospital 57 (58 pc) Discharged 31 (31 pc) Died 11 (11 pc) Signs and symptoms at admission Fever 82 (83 pc) Cough 81 (82 pc) Shortness of breath 31 (31 pc) Muscle ache 11 (11 pc) Confusion 9 (9 pc) Headache 8 (8 pc) Sore throat 5 (5 pc) Rhinorrhoea 4 (4 pc) Chest pain 2 (2 pc) Diarrhoea 2 (2 pc) Nausea and vomiting 1 (1 pc) More than one sign or symptom 89 (90 pc) Fever, cough, and shortness of breath 15 (15 pc) Comorbid conditions Any 33 (33 pc) ARDS 17 (17 pc) Acute renal injury 3 (3 pc) Acute respiratory injury 8 (8 pc) Septic shock 4 (4 pc) Ventilator -associated pneumonia 1 (1 pc) Chest x-ray and CT findings Unilateral pneumonia 25 (25 pc) Bilateral pneumonia 74 (75 pc) Multiple mottling & ground-glass opacity 14 (14 pc) Treatment Oxygen therapy 75 (76 pc) Mechanical ventilation Non-invasive (ie, face mask) 13 (13 pc) Invasive 4 (4 pc) CRRT 9 (9 pc) ECMO 3 (3 pc) Antibiotic treatment 70 (71 pc) Antifungal treatment 15 (15 pc) Antiviral treatment 75 (76 pc) Glucocorticoids 19 (19 pc) Intravenous immunoglobulin therapy 27 (27 pc)